Topical corticosteroid therapy: clobetasol propionate 0.025%

Topical corticosteroids have been the cornerstone of treatment over the last six decades for various dermatoses characterized by dry, scaly, crusted, or erythematous skin as well as those associated with inflammation and pruritus. The potency of a topical steroid depends on the specific molecule, the amount of drug reaching the target, absorption through the skin (0.25%–3%), and the formulation. Clobetasol propionate (CP) 0.025% cream formulation is a potent, fifth-generation topical corticosteroid. It is approved by the United States Food and Drug Administration to be applied twice daily for the treatment of moderate-to–severe psoriasis in adults. This case series covers the clinical experience of various dermatologists, including their expert opinion on the safety and efficacy of ImpoyzTM (CP) cream 0.025% in different skin disorders

Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment

Table S2. Spearman correlation of the expression of four glycolytic enzymes in a cohort of 380 ovarian cancers. Spearman rho correlation values (top value) along with the respective adjusted P value (bottom value) of statistically significant correlations thresholded at FDR P < 0.01 are summarised. (DOCX 21 kb

Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting.

BACKGROUND: Colorectal cancer-specific biomarkers have been used as molecular targets for fluorescent intra-operative imaging, targeted PET/MRI, and selective cytotoxic drug delivery yet the selection of biomarkers used is rarely evidence-based. We evaluated sensitivities and specificites of four of the most commonly used markers: carcinoembryonic antigen (CEA), tumour-associated glycoprotein-72 (TAG-72), folate receptor-α (FRα) and Epithelial growth factor receptor (EGFR). METHODS: Marker expression was evaluated semi-quantitatively in matched mucosal and colorectal cancer tissues from 280 patients using immunohistochemistry (scores of 0-15). Matched positive and negative lymph nodes from 18 patients were also examined. RESULTS: Markers were more highly expressed in tumour tissue than in matched normal tissue in 98.8%, 79.0%, 37.1% and 32.8% of cases for CEA, TAG-72, FRα and EGFR, respectively. Carcinoembryonic antigen showed the greatest differential expression, with tumours scoring a mean of 10.8 points higher than normal tissues (95% CI 10.31-11.21, P<0.001). Similarly, CEA showed the greatest differential expression between positive and negative lymph nodes. Receiver operating characteristic analyses showed CEA to have the best sensitivity (93.7%) and specificity (96.1%) for colorectal cancer detection. CONCLUSION: Carcinoembryonic antigen has the greatest potential to allow highly specific tumour imaging and drug delivery; future translational research should aim to exploit this

The United States COVID-19 Forecast Hub dataset

Academic researchers, government agencies, industry groups, and individuals have produced forecasts at an unprecedented scale during the COVID-19 pandemic. To leverage these forecasts, the United States Centers for Disease Control and Prevention (CDC) partnered with an academic research lab at the University of Massachusetts Amherst to create the US COVID-19 Forecast Hub. Launched in April 2020, the Forecast Hub is a dataset with point and probabilistic forecasts of incident cases, incident hospitalizations, incident deaths, and cumulative deaths due to COVID-19 at county, state, and national, levels in the United States. Included forecasts represent a variety of modeling approaches, data sources, and assumptions regarding the spread of COVID-19. The goal of this dataset is to establish a standardized and comparable set of short-term forecasts from modeling teams. These data can be used to develop ensemble models, communicate forecasts to the public, create visualizations, compare models, and inform policies regarding COVID-19 mitigation. These open-source data are available via download from GitHub, through an online API, and through R packages

A Control Technique for Unification of DG Units to the electrical network Using Fuzzy Logic Controller

This paper proposes with a control method for unification of distributed generation resources using fuzzy logic controller to the utility grid.The theme is to reduce total harmonic distortionnbsp reduction using fuzzy logic controller in utility grid while delivering to non linear loads. The proposed method provides compensation for active powernbsp reactive power and harmonic load current during connection of distributed generation resources to the utility grid. The method of proposed system is first viewed in stationary reference frame then transformed in tonbsp the synchronous orthogonal reference frame. The transformed variables are used to control the voltage source converter as heart of interfacing between DG resources and utility grid.matlab simulink model of the system is done using fuzzy logic controller.Simulation results based on total harmonic distortion reduction evenly presente

Neomycin and gentamicin detection via molecular recognition with cyclam-decorated gold nanoparticles

Herein we describe the development of cyclam-coated gold nanoparticles (cyclam-Au NPs) based sensitive colorimetric method for neomycin and gentamicin detection. The cyclam-Au NPs were characterised by UV-vis spectroscopy, fourier transform infrared spectroscopy, transmission electron microscopy techniques, dynamic light scattering and zeta potential measurements. The cyclam-Au NPs aggregated in presence of neomycin and gentamicin, which results a colour change from violet to blue. The characteristic absorption peak at 530 nm was bathochromic-shifted to a longer wavelength (660 nm). This confirms the aggregation of cyclam-Au NPs in the presence of neomycin as well as gentamicin via hydrogen bonding. The UV-vis absorption measurements employed to determine detection limit of neomycin and gentamicin. The detection limit is 1.87 × 10- 8 M and 2.35 × 10- 8 M for neomycin and gentamicin respectively